Bachem Holding AG/€BANB
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Bachem Holding AG
Bachem Holding AG is a Swiss-based company specializing in the development and manufacturing of peptides and oligonucleotides, primarily serving the pharmaceutical and biotechnology industries. With its expertise in this niche area, Bachem offers products including active pharmaceutical ingredients (APIs) and research chemicals. Founded in 1971, the company has positioned itself as a key supplier for both commercial and clinical-stage clients. Bachem has production sites in Switzerland, Germany, the United Kingdom, and the United States, allowing for a robust global presence. The company's strategic positioning benefits from its focus on high-quality, innovative manufacturing processes that comply with stringent regulatory standards.
Ticker
€BANB
Sector
Primary listing
XGAT
Employees
2,292
Headquarters
Bubendorf, Switzerland
Website
BANB Metrics
BasicAdvanced
€5.1B
36.02
€1.93
0.83
€0.91
0.67%
Price and volume
Market cap
€5.1B
Beta
0.83
52-week high
€82.70
52-week low
€46.23
Average daily volume
24K
Dividend rate
€0.91
Financial strength
Current ratio
2.437
Quick ratio
0.732
Long term debt to equity
0.008
Total debt to equity
4.475
Dividend payout ratio (TTM)
22.90%
Interest coverage (TTM)
1,035.13%
Profitability
EBITDA (TTM)
214.158
Gross margin (TTM)
31.23%
Net profit margin (TTM)
19.79%
Operating margin (TTM)
24.28%
Effective tax rate (TTM)
11.03%
Revenue per employee (TTM)
€321,660
Management effectiveness
Return on assets (TTM)
5.66%
Return on equity (TTM)
10.07%
Valuation
Price to earnings (TTM)
36.023
Price to revenue (TTM)
7.13
Price to book
3.52
Price to tangible book (TTM)
3.58
Price to free cash flow (TTM)
-36.404
Free cash flow yield (TTM)
-2.75%
Free cash flow per share (TTM)
-1.906
Dividend yield (TTM)
1.32%
Forward dividend yield
0.67%
Growth
Revenue change (TTM)
17.34%
Earnings per share change (TTM)
18.48%
3-year revenue growth (CAGR)
10.76%
10-year revenue growth (CAGR)
13.17%
3-year earnings per share growth (CAGR)
9.88%
10-year earnings per share growth (CAGR)
15.32%
3-year dividend per share growth (CAGR)
6.69%
10-year dividend per share growth (CAGR)
7.83%
Bulls say / Bears say
Bachem reported strong first-half 2025 results: group sales jumped 30.2% to CHF 313 million and EBITDA climbed 64% to CHF 91 million, with the EBITDA margin rising to 29.1%, reflecting solid demand and operational leverage (Reuters).
The company raised its full-year 2025 guidance with sales now expected to grow 13–18% in local currencies and reiterated an EBITDA margin in the high twenties. For 2026, Bachem is targeting sales above CHF 1 billion and an EBITDA margin over 30%, showing confidence in its future order book (Reuters).
The expansion of Bachem’s Building K site in Bubendorf remains on schedule, with initial manufacturing lines commissioned and GMP production expected in the second half of 2025. This will provide ton-scale peptide and oligonucleotide manufacturing, supporting future growth (BioSpace).
The Research & Specialties segment fell 8.5% year-on-year to CHF 20.8 million in the first half of 2025, exposing weakness in the lower-margin research chemicals business (Investing.com).
Bachem’s capital expenditures totaled CHF 129.1 million in the first half and are projected to top CHF 400 million for all of 2025, which could put pressure on free cash flow and raise financial leverage (Reuters).
UBS noted the midpoint of Bachem’s 2025 guidance indicates EBITDA of CHF 177 million, which is below consensus expectations of CHF 193 million, pointing to possible downside risk for profitability (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bachem Holding AG stock?
Bachem Holding AG (BANB) has a market cap of €5.1B as of September 19, 2025.
What is the P/E ratio for Bachem Holding AG stock?
The price to earnings (P/E) ratio for Bachem Holding AG (BANB) stock is 36.02 as of September 19, 2025.
Does Bachem Holding AG stock pay dividends?
Yes, the Bachem Holding AG (BANB) stock pays dividends to shareholders. As of September 19, 2025, the dividend rate is €0.91259 and the yield is 0.67%. Bachem Holding AG has a payout ratio of 22.9% on a trailing twelve-month basis.
When is the next Bachem Holding AG dividend payment date?
The next Bachem Holding AG (BANB) dividend payment date is unconfirmed.
What is the beta indicator for Bachem Holding AG?
Bachem Holding AG (BANB) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.